MEDIUMResearchTier 1
Can GLP-1 Drugs Help Fight Periodontal Diseases?
SourceDecisions in DentistryTier 1Clinical & Visual
By Amber M. Nehme, RDH, BSDH, MEd
Originally at decisionsindentistry.com
Summary & scoring by The Bell Brief (Dr. Jennifer Bell) using the Drill-Down Protocol (Drill-Down Score) — not the original publisher.
Why it matters for dental
GLP-1 receptor agonists (semaglutide, liraglutide) may reduce systemic inflammation that drives periodontitis, giving general dentists and periodontists a new adjunct to consider when treating obese or diabetic patients.
Key points
- GLP-1 drugs are FDA-approved for type-2 diabetes and weight loss; their anti-inflammatory effects could slow attachment loss and pocket depth progression.
- Clinicians must monitor for oral side effects—dry mouth, taste changes, and delayed gastric emptying that may increase caries or candidiasis risk.
- No dental-specific RCTs yet; current evidence is limited to systemic reviews linking GLP-1 therapy to lower CRP and IL-6 levels.
- DSOs and practices with high Medicaid or diabetic patient panels should track emerging prescribing patterns that may influence periodontal treatment planning and recall intervals.
Who should care
SpecialistAcademiaOwner
Read the original on Decisions in Dentistry
Full reporting and any paywall content live on decisionsindentistry.com. We summarize and score; we do not republish.